NEW DELHI: Dr Reddy’s LaboratoriesBSE 0.77 % (DRL) today said its acute migraine treatment injection ZembraceSymTouch is now commercially available in the US market. “Promius Pharma LLC, a subsidiary of DRL announced today that ZembraceSymTouch injection is now commercially available in the US,” DRL said in a BSE fling. The company received an approval from the US Food and Drug Administration (USFDA) for ZembraceSymTouch injection in January this year.
ZembraceSymTouch is available as a prefilled, ready to use, single dose disposable injector. At the time of USFDA approval, DRL had said the new product will be marketed in the US by Promius Pharma.